Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Saokaew, Surasak ^a,b,c   Tassaneeyakul, Wichittra ^d   Maenthaisong, Ratree ^e   Chaiyakunapruk, Nathorn ^a,f,g,h  

^a NARESUAN UNIVERSITY   (Thailand)

^b UNIVERSITY OF PHAYAO   (Thailand)

^c UNIVERSITY OF UTAH   (United States)

^d KHON KAEN UNIVERSITY   (Thailand)

^e MAHASARAKHAM UNIVERSITY   (Thailand)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g MONASH UNIVERSITY MALAYSIA   (Malaysia)

^h UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; HLA B ANTIGEN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION ANALYTIC MODEL; FATALITY; GENETIC SCREENING; GOUT; HEALTH CARE COST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; PHARMACOGENETICS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STATISTICAL MODEL; STEVENS JOHNSON SYNDROME; THAILAND; TOXIC EPIDERMAL NECROLYSIS; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; GENETICS; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

ALLOPURINOL; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GENETIC TESTING; HLA-B ANTIGENS; HUMANS; STEVENS-JOHNSON SYNDROME; THAILAND; TREATMENT OUTCOME;

EID: 84899627684     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094294     Document Type: Article

References (46)

1. Roujeau JC, Stern RS (1994) Severe adverse cutaneous reactions to drugs. N Engl J Med 331(19):1272-1285. (Pubitemid 24333193)
2. Chan H, Stern R, Arndt K, Langlois J, Jick S, et al. (1990) The incidence of erythema multiforme, Sevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 126(1):43-47. (Pubitemid 20040979)
3. Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, et al. (1996) Epidemiology of erythema exsudativum multiform emajus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 49(7):769-773. (Pubitemid 26280728)
4. Gerull R, Nelle M, Schaible T (2011) Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review. Crit Care Med 39(6):1521-1532.
5. Harr T, French LE (2010) Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 5:39-49.
6. Yip LW, Thong BY, Lim J, Tan AW, Wong HB, et al. (2007) Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 62(5):527-531. (Pubitemid 46608353)
7. Di Pascuale MA, Espana EM, Liu DT, Kawakita T, Li W, et al. (2005) Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology 112(5):904-912. (Pubitemid 40631513)
8. Somkrua R, Saokaew S, Lohitnavy M, Chaiyakunapruk N (2011) Association of HLA-B 5801 allele and allopurinol induced Stevens-Johnson Syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 12:118-127.
9. Chiu MLS, Hu M, Ng MHL, Yeung CK, Chan JCY, et al. (2012) Association between HLA-B 58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol 167:44-49.
10. Rheumatism Association of Thailand (2012) Guideline for management of gout Available: http://thairheumatology.org/attchfile/Guideline%20for%20 Management%20of%20Gout.pdf.Accessed 17 August 2013.
11. Hamburger M, Herbert SB, Adamson III TC, Basile J, Bass L, et al. (2011) Recommendations for the diagnosis and management of gout and hyperuriccemia. Postgrad Med 123(6; Suppl 1):3-36.
12. Burns CM, Wortmann RL (2012) Latest evidence on gout management: what the clinician needs to know. Ther Adv Chronic Dis 3(6):271-286.
13. Teng GG, Nair R, Saag KG (2006) Pathophysiology, clinical presentation and treatment of gout. Drugs 66:1547-1563. (Pubitemid 44376344)
14. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, et al. (2012) American College of Rheumatology guidelines for management of gout. Part 1: Systematic non-pharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64(10):1431-1446.
15. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, et al. (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1312-1324. (Pubitemid 44620440)
16. Chao J, Terkeltaub R (2009) A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 11:135-140.
17. Scott JT (1966) Comparison of allopurinol and probenecid. Ann rheum Dis 25:623-626.
18. Wortmann RL (2002) Gout and hyperuricemia. Curr Op in Rheumatol 14:281-286. (Pubitemid 34439094)
19. Atzori L, Pinna AL, Mantovani L, Ferreli C, Pau M, et al. (2012) Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department-Cagliari University (Italy). J Eur Acad Dermatol Venereol 26(11):1424-1430.
20. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, et al. (2009) Strong association between HLA-B 5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 19(9):704-709.
21. Thai working group on health technology assessment guidelines in Thailand (2008) Thai health technology assessment guideline. J Med Assoc Thai 91(2):S1-S88.
22. Riewpaiboon A. (2010) Standard cost lists for health technology assessment. Available: http://www.hitap.net/costingmenu/. Accessed 27 July 2013.
23. Suwankesawong W (2011) Report of drug-related severe cutaneous adverse reaction: SJS/TEN. Med Health Prod Bull1 4(1):28-32.
24. Perez-Ruiz F, Calabozo C, Herrero-Beites A, Garcia-Erauskin G, Pijoan J (2000) Improvement in renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 86:287-91.
25. Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS (1995) Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysisdisease spectrum. Ophthalmology 102(11):1669-1676.
26. Limkobpaiboon S, Panomvana Na Ayudhya D, Dhana N, Jongjareanprasert K (2010) Prevalence and mortality rate of severe cutaneous adverse reactions in Siriraj hospital. Chula Med J 54(5):467-478.
27. Romphruk AV, Romphruk A, Kongmaroeng C, Klumkrathok K, Paupairoj C, et al. (2010) HLA class I and II alleles and haplotypes in ethnic Northeast Thais. Tissue Antigens 75:701-711.
28. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR (2011) Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acid Research 39, D913-D919 Available http://www.allelefrequencies.net/Accessed 14July 2013.
29. Hall GH (1967) The clinical application of Bayes' theorem. Lancet 9;2(7515):555-7.
30. World Health Organization (2011) Global Health Observatory Data Repository. Available: http://apps.who.int/ghodata/?vid =61640. Accessed 17 June 2012.
31. Beard SM, von Scheele BG, Nuki G, Pearson IV (2013) Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ: DOI 10.1007/s10198-013-0486-z.
32. Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, et al. (2003) Utility assessment among patients with dry eye disease. Ophthalmology 110(7):1412-1419. (Pubitemid 36842481)
33. Buchholz P, Steeds CS, Stern LS, Wiederkehr DP, Doyle JJ, et al. (2006) Utility assessment to measure the impact of dry eye disease. Ocul Surf 4(3): 155-161. (Pubitemid 351902294)
34. Ara R, Brazier J (2012) Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods. Med Care 50(5):452-459.
35. Altman DG, Bland JM (1994) Diagnostic tests 2: predictive values. BMJ 309(6947):102. (Pubitemid 24216428)
36. Hobbs FD, Delaney BC, Fitzmaurice DA, Wilson S, Hyde CJ, et al. (1997) A review of near patient testing in primary care. Health Technol Assess 1(5):1-229.
37. Bank of Thailand (2013) Foreign Exchange Rates. Available: http://www.bot. or.th/english/statistics/financialmarkets/exchangerate/-layouts/ application/exchangerate/exchangerate.aspx. Accessed 8 July 2013.
38. Wises K, Chunhasewee S, Rattanapan P (2008) Cost of management for Stevens-Johnson Syndrome or toxic epidermal necrolysis. Phitsanulok: Naresuan University.
39. Drugs and Medical Supplies Information Center (DMSIC), Ministry of Public Health. (2013) Reference drug price. Available: http://dmsic.moph.go.th/price/ price1-1.php?method =drug. Accessed 9July 2013.
40. Bureau of trade and economic indices, Ministry of Commerce Thailand (2013) Report of consumer price index of Thailand. Available: www.price.moc.go.th/content1.aspxcid = 1. Accessed 7July 2013.
41. Ministry of Public Health (2009) Public Health Statistics. Bangkok.
42. Permsuwan U, Guntawongwan K, Buddhawongsa P (2008) Handling time in economic evaluation studies. J Med Assoc Thai 91(Suppl2):S53-S58.
43. Sub-committee of Thai Working Group on Health Technology Assessment (2013) Meeting report of 2nd annual meeting.
44. Limwattananon S (2008) Handling uncertainty of the economic evaluation result: sensitivity analysis. J Med Assoc Thai (Suppl 2):S59-S65.
45. Briggs AH (2000) Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17(5):479-500. (Pubitemid 30398806)
46. Teerawattananon Y, Chaikledkaew U (2008) Thai health technology assessment guideline development. J Med Assoc Thai (Suppl 2):S11-S15.